Endothelium-specific delivery of let-7 miR for treating Atherosclerosis

• Atherosclerosis is responsible for the vast majority of cardiovascular disease. Currently available therapy (statins) slow down, but do not reduce the disease.
• Suppression of TGF, FGF and let-7 miRNA signaling in the endothelium can be used to reduce the size of atherosclerotic plaque and decrease overall atherosclerosis burden.
• A genetic proof of this concept has been obtained in mice using endothelial-specific TGFR1/R2 knockout.
• Additional supporting data available from human samples
• Indications: atherosclerosis, CAD/MI/angina, stroke, peripheral vascular disease
• Lead Innovator: Michael Simons, M.D.
• References: Nat Metab 2019 Sep;1(9):912-926
• IP status: US 16/086,809